Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
Scott T Aaronson, Andrew van der Vaart, Tammy Miller, Jeffrey LaPratt, Kimberly Swartz, Audrey Shoultz, Margo Lauterbach, Trisha Suppes, Harold A Sackeim
American Journal of Psychiatry January 1, 2025 DOI: 10.1176/appi.ajp.20231063 via OpenAlex
Summary
AI-generated from the abstractIn an open-label study, psilocybin appears effective and safe for people with severe treatment-resistant depression, supporting further research into psychedelics for this group, including how post-traumatic stress disorder may affect outcomes.
Study at a glance
| Characteristics | Open-label study Peer reviewed |
|---|---|
| Population | People with severe treatment-resistant depression |
| Intervention | Psilocybin |
| Topics | Depression Psilocybin |
| Keywords | Psychedelics hallucinogens Psychedelic drugs Drug research |
| Citations | 31 |
| Key finding | Psilocybin suggests efficacy and safety in severe treatment-resistant depression and supports further study, including consideration of PTSD interaction effects. |
Abstract
This open-label study suggests efficacy and safety of psilocybin in severe TRD and supports further study of psychedelics in this population, including consideration of PTSD interaction effects.